MedPath

Pre-Exercise for Allogeneic Stem Cell Transplant Patients

Not Applicable
Terminated
Conditions
Cancer, Hematological
Registration Number
NCT03080792
Lead Sponsor
University Hospital Heidelberg
Brief Summary

The PRESENT-P study is a one-arm exercise intervention study for hematological cancer patients prior allogeneic stem cell transplantation (allo-HCT). This pilot study will investigate in a prehabilitation approach the safety and feasibility of high-intensity exercise program directly prior transplantation.

Detailed Description

The major objective of PRESENT-P is to investigate the feasibility and safety of a high intensity endurance exercise training (HIIT) and progressive resistance exercise prior allo-HCT. This multicenter pilot study will include n=30 patients. Patients perform two supervised exercise sessions per week. Recruitment take place 6-12 weeks prior allogeneic stem cell transplantation. Further aims of this pilot study are: to estimate the number of eligible patients, evaluate the recruitment procedure, and to explore the effect of HIIT prior allo-HCT on maximal oxygen uptake (VO2peak),submaximal endurance capacity, muscle strength, patient-reported-outcomes including QoL and physical functioning.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • Hematological cancer, e.g. AML, CLL, MM
  • Scheduled for allo-HCT at the University Clinic Heidelberg or other cooperation sites within the next 4-12 weeks
  • Patients ≥ 18 years of age
  • Sufficient German language skills
  • Willing/ able to train at the provided exercise facilities twice per week and to take part in the scheduled testing
  • Signed informed consent
Exclusion Criteria
  • Heart insufficiency > NYHA III or uncertain arrhythmia
  • Uncontrolled hypertension
  • Severe renal dysfunction (GFR < 30%, Creatinine> 3mg/dl)
  • Reduced standing or walking ability
  • Insufficient hematological capacity (either hemoglobin value below 8 g/dl or thrombocytes below 30.000/µL)
  • Any other comorbidities that preclude participation in the exercise programs
  • Engaging in systematic intense exercise training (at least 1h twice per week)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Safety of supervised high-intensity exercise aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer4-12 weeks

Minor and Major adverse events that are related to the exercise intervention

Feasibility of supervised high-intensity aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer patients. Measured as adherence to the training protocol4-12 weeks

Adherence is defined as \>50% of prescribed exercise sessions completed.

Secondary Outcome Measures
NameTimeMethod
Change in maximal voluntary isometric hand-grip strength4-12 weeks
Change in Fatigue4-12 weeks

Multidimensional Fatigue Inventory, MFI 20

Change in maximal oxygen uptake (VO2peak), assessed in a maximal incremental exercise test (CPET) on a cycle ergometer4-12 weeks
Body Composition4-12 weeks

Bioelectrical impendance analysis

Estimate the number of eligible patients12 month
Change in Quality of Life (QoL)4-12 weeks

European Research and Treatment in Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Change in maximal voluntary isometric contraction (MVIC) in a stationary dynamometer test4-12 weeks
Change in submaximal endurance performance, assessed in a 6-minute walk test (6MWT)4-12 weeks
Change in depression4-12 weeks

Center for Epidemiologic Studies Depression Scale, CES-D

Evaluation of recruitment procedures12 month

Description of possible recruiting procedures in the ambulatory and stationary setting.

Trial Locations

Locations (5)

University Hospital Carl Gustav Carus Dresden

🇩🇪

Dresden, Germany

UCT Frankfurt / Hospital North-West

🇩🇪

Frankfurt, Germany

Medical Center - University Freiburg

🇩🇪

Freiburg, Germany

Heidelberg University Hospital

🇩🇪

Heidelberg, Germany

University of Colone

🇩🇪

Cologne, Germany

© Copyright 2025. All Rights Reserved by MedPath